BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37491289)

  • 21. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
    Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
    Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
    Trinkaus M; Vranic A; Dolenc VV; Lah TT
    Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis.
    Shin HK; Park JH; Cho YH; Kim YH; Hong SH; Kim JH; Roh SW; Jeon SR
    World Neurosurg; 2021 Jul; 151():e718-e730. PubMed ID: 33974984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of pediatric CNS meningiomas: CCHE-57357 experience in 39 cases.
    El Beltagy MA; Enayet AE; Atteya MME; Reda M; Refaat A; Taha H; Ahmed S; Abdelaziz A
    Childs Nerv Syst; 2019 Aug; 35(8):1323-1331. PubMed ID: 31127346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
    Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
    Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
    Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
    Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.
    Wang XQ; Jiang CC; Zhao L; Gong Y; Hu J; Chen H
    J Neurosurg Pediatr; 2012 Nov; 10(5):423-33. PubMed ID: 22938082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
    Korshunov A; Shishkina L; Golanov A
    Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
    J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
    Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
    J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
    Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
    J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.